Affiliation: Allegheny General Hospital
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsSusan Manzi
Allegheny Singer Research Institute, West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, Pennsylvania 15224, USA
Ann Rheum Dis 71:1833-8. 2012..To evaluate the effects of belimumab versus placebo, plus standard systemic lupus erythematosus (SLE) therapy, on organ domain-specific SLE disease activity...
- Progression of Cardiovascular Disease in Lupus.Susan Manzi; Fiscal Year: 2010..We are now uniquely positioned to make additional seminal observations regarding the progression of this pathologic process and to ultimately intervene therapeutically. ..